Latest advances in the treatment of hidradenitis (swallowing)

Diagnosis of hidradenitis

The diagnosis of hidradenitis is based on the characteristics and distribution of the lesions, as well as the chronicity and recurrence of symptoms. The morphology of hidradenitis lesions includes: papules, nodules, abscesses, sinus tracts, fistulas and scars. These lesions persist for at least three months and typically extend to the axillary, inframammary, inguinal, perineal, and gluteal regions.

The Hurley staging system is commonly used to determine the severity of hidradenitis.

Hurley Stage I indicates a mild form of the disease, while stages II and III represent moderate to severe forms. diseases accordingly.

Visual Analogue Pain Scale and Dermatological Quality of Life Index can help assess the impact of the disease on daily lifej. In addition, ultrasound has become an effective diagnostic method for identifying fistula tracts and signs of active inflammation.

New Treatments for Hidradenitis

Appropriate drug treatment for hidradenitis It depends on the severity of the disease:

1. While Local therapy and laser hair removal may be sufficient in mild cases; in more severe cases, systemic therapy with oral antibiotics (doxycycline, clindamycin and rifampicin) and corticosteroid injections may be required.
   
2. operation It is used in many cases of hidradenitis. Sometimes the tissue is removed to expose the fistulas. Surgical removal is an option for people with persistent or severe symptoms. It involves removing all affected skin. We sometimes use a CO2 laser to repair superficial damage.
   
3. Additional measures to this treatment include maintaining good skin hygiene, minimizing injuries, providing psychological support and avoiding diets with a high glycemic load..
   
4. In cases of moderate to severe hidradenitis or resistance to previous treatment: Targeted immunomodulatory therapy is gaining popularity.. Biologic drugs such as adalimumab and infliximab have been used to control flare-ups.
   
5. Recently it was shown that secukinumabA human monoclonal antibody targeting IL-17A is effective in the treatment of moderate to severe hidradenitis. Results from two studies showed that a significant proportion of patients treated with secukinumab experienced a 50% reduction in the number of inflammatory nodules. Other drugs such as bimekizumab are also effective in this disease, which opens a very interesting and wide therapeutic window for patients suffering from this debilitating disease.